Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting
Interim data from Phase 1 study in patients with Ewing sarcoma show TK216 has been generally well tolerated One of…